Slow-release 5-amino-salicylic acid (Pentasa) for the treatment of active Crohn's disease.
A double-blind, placebo-controlled trial of a slow-release preparation of 5-amino-salicylic acid (Pentasa) has been performed in 40 patients with active Crohn's disease. Over a 6-week period, Pentasa (1.5 g daily) was no different to the dummy tablet in terms of clinical activity (Harvey-Bradsh...
Prif Awduron: | Mahida, Y, Jewell, D |
---|---|
Fformat: | Journal article |
Iaith: | English |
Cyhoeddwyd: |
1990
|
Eitemau Tebyg
-
Topical treatment of distal ulcerative colitis with 4-amino-salicylic acid enemas.
gan: Selby, W, et al.
Cyhoeddwyd: (1984) -
DECISION TREE CONSTRUCTION AND COST-EFFECTIVENESS ANALYSIS OF TREATMENT OF ULCERATIVE COLITIS WITH PENTASA®MESALAZINE 2 G SACHET
gan: Alvaro Mitsunori NISHIKAWA, et al. -
Macrophage and lymphocyte subpopulations in magnifying endoscopic lesions of Crohn's disease.
gan: Gionchetti, P, et al.
Cyhoeddwyd: (1988) -
Enhanced production of interleukin 1-beta by mononuclear cells isolated from mucosa with active ulcerative colitis of Crohn's disease.
gan: Mahida, Y, et al.
Cyhoeddwyd: (1989) -
Immunoglobulin production by isolated intestinal mononuclear cells from patients with ulcerative colitis and Crohn's disease.
gan: Wu, K, et al.
Cyhoeddwyd: (1989)